[en] Metabolic and morphologic abnormalities in persons with HIV remain common contributors to stigma and morbidity. Increased abdominal circumference and visceral adiposity were first recognized in the late 1990s, soon after the advent of effective combination antiretroviral therapy. Visceral adiposity is commonly associated with metabolic abnormalities including low HDL-cholesterol, raised triglycerides, insulin resistance, and hypertension, a constellation of risk factors for cardiovascular disease and diabetes mellitus known as "the metabolic syndrome". Medline and conference abstracts were searched to identify clinical research on factors associated with visceral adiposity and randomized studies of management approaches. Data were critically reviewed by physicians familiar with the field. A range of host and lifestyle factors as well as antiretroviral drug choice were associated with increased visceral adiposity. Management approaches included treatment switching and metformin, both of which have shown benefit for insulin-resistant individuals with isolated fat accumulation. Testosterone supplements may also have benefits in a subset of individuals. Supra-physiological doses of recombinant human growth hormone and the growth hormone releasing hormone analog tesamorelin both significantly and selectively reduce visceral fat over 12-24 weeks; however, the benefits are only maintained if doping is continued. In summary, the prevention and management of visceral adiposity remains a substantial challenge in clinical practice.
Disciplines :
Immunology & infectious disease
Author, co-author :
Moyle, Graeme
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén.
Martinez, Esteban
Domingo, Pere
Guaraldi, Giovanni
Raffi, Francois
Behrens, Georg
Reiss, Peter
Language :
English
Title :
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.
Ault A. FDA warns of potential protease-inhibitor link to hyperglycaemia. Lancet. 1997;349:1819.
Munk B. Protease paunch? Posit Aware. 1997;8:20-1.
Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS. 1998;12:2499.
Koppel K, Bratt G, Rajs J. Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. AIDS. 1999;13:1993-4.
Hamilton B, Paglia D, Kwan A, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med. 1995;1:953-6.
Kern P, Saghizadeh M, Ong J, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111-19.
Wajchenberg B. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738.
Vague J. The distinction of android and gynoid obesities as the base for their prognosis. Sem Hop. 1955;31:3503-9.
Balkau B, Deanfield J, Després J, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation. 2007;116:1942-51.
Lu M, Ye W, Adami H, Weiderpass E. Prospective study of body size and risk for stroke amongst women below age 60. J Intern Med. 2006;260:442-50.
Joy T, Keogh H, Hadigan C, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008;47:174-84.
Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr. 2008;48:142-8.
Fox K, Després J, Richard A, et al. Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91 246 ambulant patients in 27 European Countries. Eur Heart J. 2009;30:3055-63.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
Brown T, Xu X, John M, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;13;6:8.
Schoen R, Evans R, Sankey S, Weissfeld J, Kuller L. Does visceral adipose tissue differ from subcutaneous adipose tissue in fatty acid content? Int J Obes Relat Metab Disord. 1996;20:346-52.
Ross R, Shaw K, Rissanen J, et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. Am J Clin Nutr. 1994;59:1277-85.
Ross R. Magnetic resonance imaging provides new insights into the characterization of adipose and lean tissue distribution. Can J Physiol Pharmacol. 1996;74:778-85.
Baumgartner R, Heymsfield S, Roche A, Bernardino M. Abdominal composition quantified by computed tomography. Am J Clin Nutr. 1988;48:936-45.
Janssen I, Ross R. Effects of sex on the change in visceral, subcutaneous adipose tissue and skeletal muscle in response to weight loss. Int J Obes Relat Metab Disord. 1999;23:1035-46.
Ross R, Leger D, Morris D. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol. 1992;72:787-95.
Ross R, Shaw K, Martel Y, et al. Determination of total and regional adipose tissue distribution by magnetic resonance imaging in android women. Basic Life Sci. 1993;60:177-80.
Ross R, Shaw K, Martel Y, de Guise J, Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am J Clin Nutr. 1993;57:470-5.
Koester R, Hunter G, Snyder S, Khaled M, Berland L. Estimation of computerized tomography derived abdominal fat distribution. Int J Obes Relat Metab Disord. 1992;16:543-54.
Liu K, Chan Y, Chan W, et al. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes Relat Metab Disord. 2003;27:1267-73.
Abate N, Burns D, Peshock R, Garg A, Grundy S. Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res. 1994;35:1490-6.
He Q, Engelson E, Wang J, et al. Validation of an elliptical anthropometric model to estimate visceral compartment area. Obes Res. 2004;12:250-7.
Yang G, Myerson S, Chabat F, Pennell D, Firmin D. Automatic MRI adipose tissue mapping using overlapping mosaics. MAGMA. 2002:14;39-44.
Poll L, Wittsack H, Koch J, et al. Quantification of total abdominal fat volumes using magnetic resonance imaging. Eur J Med Res. 2002;7:347-52.
Poll L, Wittsack H, Koch J, et al. A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging. Magn Reson Imaging. 2003;21:631-6.
Shen W, Punyanitya M, Wang Z, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr. 2004;80:271-8.
Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333-8.
Han T, Kelly I, Walsh K, Greene R, Lean M. Relationship between volumes and areas from single transverse scans of intra-abdominal fat measured by magnetic resonance imaging. Int J Obes Relat Metab Disord. 1997;21:1161-6.
Thomas E, Bell J. Influence of undersampling on magnetic resonance imaging measurements of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord. 2003;27:211-18.
Williams M, Hunter G, Kekes-Szabo T. Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. Int J Obes Relat Metab Disord. 1996;20:613-17.
Elbers J, Haumann G, Asscheman H, Seidell J, Gooren LJ. Reproducibility of fat area measurements in young, non-obese subjects by computerized analysis of magnetic resonance images. Int J Obes Relat Metab Disord. 1997;21:1121-9.
Seidell J, Bakker C, van der Kooy K. Imaging techniques for measuring adipose-tissue distribution-a comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr. 1990;51:953-7.
Staten M, Totty W, Kohrt W. Measurement of fat distribution by magnetic resonance imaging. Invest Radiol. 1989;24:345-9.
Gerard E, Snow R, Kennedy D, et al. Overall body fat and regional fat distribution in young women: quantification with MR imaging. Am J Roentgenol. 1991;157:99-104.
Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:493-6.
van der Kooy K, Seidell J. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord. 1993;17:187-96.
Minocci A, Savia G, Lucantoni R, et al. Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord. 2000;24:1139-44.
Hashimoto M, Akishita M, Eto M, et al. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord. 1998;22:477-84.
Suzuki R, Watanabe S, Hirai Y, et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med. 1993;95:309-14.
Yamamoto M, Egusa G, Hara H, Yamakido M. Association of intraabdominal fat and carotid atherosclerosis in non-obese middle-aged men with normal glucose tolerance. Int J Obes Relat Metab Disord. 1997;21:948-51.
Vlachos I, Hatziioannou A, Perelas A, Perrea D. Sonographic assessment of regional adiposity. Am J Roentgenol. 2007;189:1545-53.
Park Y, Heymsfield S, Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord. 2002;26:978-83.
Rush E, Chandu V, Plank L. Prediction of fat-free mass by bioimpedance analysis in migrant Asian Indian men and women: a cross validation study. Int J Obes (Lond). 2006;30:1125-31.
Pateyjohns I, Brinkworth G, Buckley J, et al. Comparison of three bioelectrical impedance methods with DXA in overweight and obese men. Obesity. 2006;14:2064-70.
Ryo M, Maeda K, Onda T, et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care. 2005;28:451-3.
Mulligan K, Glesby M, Freedland E. Sex differences in the correlations between baseline anthropometric measurements and fat distribution in HIV-infection-associated adipose redistribution (HARS): Antivir Ther. 2007;12(suppl 2):L27.
Scherzer R, Shen W, Bacchetti P, et al. Simple anthropometric measures correlate with metabolic risk indicators as strongly as magnetic resonance imaging-measured adipose tissue depots in both HIV-infected and control subjects. Am J Clin Nutr. 2008;87:1809-17.
Caan B, Armstrong M, Selby J, et al. Changes in measurements of body fat distribution accompanying weight change. Int J Obes Relat Metab Disord. 1994;18:397-404.
Carr A, Emery S, Law M, et al. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-35.
Savés M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1397-405.
Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. J Acquir Immune Defic Syndr. 2002;31:50-5.
Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr. 2003;34:58-61.
Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
Jacobson D, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40;1837-45.
Cofrancesco J, Freedland E, McComsey G. Treatment options for HIV-associated central fat accumulation. AIDS Patient Care STDS. 2009;23:5-18.
Poizot-Martin I, Obry-Roguet V, Biron C, et al. Abdominal adiposity remains highly prevalent in French HIV-infected patients having initiated antiretroviral therapy after 2005. EACS 2009; Cologne, Germany [abstract PS11/1].
Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-31.
Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562-71.
Martínez E, Mocroft A, García-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.
Lichtenstein K. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39:395-400.
Worm S, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24:427-35.
Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J Clin Endocrinol Metab. 2007;92:2506-12.
Friis-Moller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
Friis-Møller N, Reiss P, Sabin C, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35.
Currier J, Lundgren J, Carr A, et al Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-35.
Budoff M, Shaw L, Liu S, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. JACC. 2007;49:1860-70.
Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in HIV infected subjects. Atherosclerosis. 2010;208:222-7.
Guaraldi G, Zona S, Orlando G, et al. Progression of subclinical atherosclerosis in HIV Infected Patients. ADRLH-45. 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. October 2009, Philadelphia, USA.
Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy. Clin Infect Dis. 2001;32:130-9 .
Bonora E, Kiechi S, Willeit J, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population. Diabetes Care. 2007;30:318-24.
Hanley A, Williams K, Stern M, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25:1177-84.
Visnegarwala F, Chen L, Raghavan S, et al. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients coinfected with hepatitis C virus (HCV) and HIV-1 compared to patients without coinfection. J Infect. 2005;50:331-7.
Palacios R, Merchante N, Macias J, et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther. 2006;11:529-35.
Grunfeld C, Rimland D, Gibert C, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr. 2007;46:283-90.
Rietsche, P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metabolism. 2001;86;504-10.
Koutkia P, Eaton K, You S, et al. Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution. AIDS. 2006;20:855-62.
Koutkia P, Meininger G, Canavan B, et al. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E296-303.
Lo J, You S, Wei J, Canavan B, Grinspoon S. Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf). 2009 [epub ahead of print].
Guaraldi G, Murri R, Orlando G, et al. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev. 2008;10:152-61.
Luzi K, Guaraldi G, Murri R, et al. Body image is a major determinant of sexual dysfunction in stable HIV-infected women. Antivir Ther. 2009;14:85-92.
Guaraldi G, Luzi K, Murri R, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antivir Ther. 2007;12:1059-65.
Luzi K, Guaraldi G, Murri R, et al. Body image is a major determinant of sexual dysfunction in stable HIV-infected women. Antivir Ther. 2009;14:85-92.
Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials. 2003;4:99-106.
Grunfeld C, Kotler D, Shigenaga J, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154-62.
Macallan D, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med. 1995;333:83-8.
Macallan D, Noble C, Baldwin C, et al. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr. 1993;58:417-24.
Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-9.
Calmy A, Carey D, Mallon PW, et al. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med. 2008;9:101-10.
Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr. 2008;48:44-52. (Pubitemid 351600858)
Mulligan K, Parker R, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41:590-7.
Haubrich R, Riddler S, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109-18.
Shlay J, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005:38:147-55.
Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-47.
Shlay J, Sharma S, Peng G, et al. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51:298-304.
Pozniak A, Gallant J, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-40.
Vroenraets S, Fernandez Garcia E, Jackson A, et al. Both once-daily saquinavir/ritonavir and atazanavir/ritonavir, when combined with tenofovir/emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reduction in glomerular filtration over 48 weeks: the BASIC trial. EACS 2009; Cologne, Germany [abstract LBPS10/6].
Moyle G, Yang R, Wirtz V, et al. Body composition changes in treatment-naive patients treated with boosted PIs plus TDF/FTC: results from the CASTLE study through 96 weeks. EACS 2009; Cologne, Germany [abstract LBPS 11/6].
van Vonderen M, van Agtmael M, Hassink E, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One. 2009;4:e5647.
Cameron D, da Silva B, Arribas J, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198:234-40.
Shlay J, Bartsch G, Peng, G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007;44:506-17.
DeJesus E, Lazzarin A, Lennox A, et al. Metabolic profiles and body composition changes in treatment-naïve HIV-infected patients treated with raltegravir 400 mg bid-based vs. efavirenz 600 mg qhs-based combination therapy: 48-week data. ICAAC 2009. H-329.
Stanley T, Joy T, Hadigan C, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS. 2009;23:1349-57.
Moyle G, Girard J-M, Andrade J, et al. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study. XVII International AIDS Conference, Mexico City, 2008; [abstract MOPDB103].
Moyle G, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-8.
Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917-25.
Moyle G, Baldwin C, Comitis S, et al. Management of metabolic and body shape changes occurring during protease inhibitor (PI) therapy by substitution of PI with efavirenz in virologically controlled HIV-1 positive persons: A single arm observational cohort. J Acquir Immune Defic Syndr. 2001;28:399-401.
Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-15.
Moyle G, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-50.
Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother. 2009;63:998-1005.
Hendricks K, Dong K, Tang A, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr. 2003;78:790-5.
Dolan S, Frontera W, Librizzi J, et al. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med. 2006;166:1225-31.
Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS. 1999;13:1373-5.
Thoni G, Fedou C, Brun J, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab. 2002;28:397-404.
Terry L, Sprinz E, Stein R, et al. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc. 2006;38:411-17.
Engelson E, Agin D, Kenya S, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006;55:1327-36.
Fitch K, Anderson E, Hubbard J, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS. 2006;20:1843-50.
Bhasin S, Parker R, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92:1049-57.
Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140:786-94.
Slama L, Lanoy E, Valantin M, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther. 2008;13:67-76.
Macallan D, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials. 2008;9:253-67.
Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429-38.
Sutinen J, Hakkinen A, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther. 2003;8:199-207.
Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000;284:472-7.
Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med. 2007;8:420-6.
Mulligan K, Yang Y, Wininger D, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21:47-57.
Driscoll S, Meininger G, Lareau M, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS. 2004;18:465-73.
Moyle G, Daar E, Gertner J, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:367-75.
Kotler D, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumula tion and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239-52.
Grunfeld C, Thompson M, Brown S, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribu tion syndrome: 12-week induction and 24-week maintenance therapy. J Acquir Im mune Defic Syndr. 2007;45:286-97.
Luzi L, Meneghini E, Oggionni S, et al. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. Eur J Endocrinol. 2005;153:781-9.
Bickel M, Zangos S, Jacobi V, et al. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. HIV Med. 2006;7:397-403.
Andersen O, Haugaard S, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest. 2004;34:561-8.
Engelson E, Glesby M, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002;30:379-91.
Lo J, You S, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300:509-19.
Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70.
Falutz J, Allas S, Mamputu J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719-28.
Falutz J, Potvin D, Mamputu J-C, et al. Effects of Tesamorelin, a growth hormone releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized, placebo-controlled, trial with a safety extension. J Acquir Immune Defic Syndr. 2010 [Epub ahead of print].
Lee J, Chan J, Sourlas E, Raptopoulos V, Mantzoros C. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91:2605-11.
Klein S, Fontana L, Young V, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-57.
Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord. 2002;26:193-9.
